Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Pharmacogenomics
(ISSN: 1462-2416, 1744-8042)
This journal no longer participates in Medscape Publishers' Circle Program. No new articles will be republished.
Does the presence of polymorphisms in certain genes and alterations in their miRNA expression affect in vitro chemosensitivity to cisplatin and gemcitabine?
The agent 5-fluorouracil remains one of the most widely used drugs for the treatment of solid tumors, but 10-20% of patients experience severe adverse effects. Can these be predicted?
This review investigates the contributions of genomic factors in explaining sub-optimal response to currently used antiemetics for combating the nausea and vomiting of chemotherapy.
CYP2D6 is crucial for the metabolism of many drugs, but currently phenotyping requires administration of a probe drug. Could a urinary biomarker provide a noninvasive method of CYP2D6 phenotyping?
Many patients don't adequately respond to treatment with drugs used in inflammatory diseases. Could predictive biomarkers to drug response--both genetic and non-genetic--be identified?
Single-nucleotide polymorphisms in ABC drug transporters alter expression and circulating tenofovir in healthy South African women exposed to pre-exposure prophylaxis.
Mission Statement:
Pharmacogenomics is a peer-reviewed journal presenting reviews, original research and reports by the scientists, clinicians and decision-makers who are most closely involved in this rapidly developing area.
